Buscar

Renown Health se complace en anunciar que Susan Lee, DO, MBA, se desempeñará como directora de operaciones del Renown South Meadows Medical Center. La Dra. Lee asume su nueva función el 7 de marzo y sucede a Chris Nicholas, quien renunció el mes pasado para tomar un puesto en un sistema de salud de Florida. Tony Slonim, MD, DrPH, presidente y director ejecutivo de Renown Health, anunció hoy el ascenso interno de la Dra. Lee con las siguientes palabras: “En consonancia con nuestra visión de mejorar la salud de la comunidad, empoderamos a los líderes para que desempeñen un papel más importante en la mejora de las experiencias de los médicos, los empleados y los pacientes; en la ampliación de servicios para nuestra comunidad; en la prestación de atención exacta y confiable, y en el cumplimiento de estándares rigurosos de excelencia y eficacia operativa”. El Dr. Slonim comentó que estaba entusiasmado ya que “La Dra. Lee amplía su función, promueve un espíritu de unidad en toda la empresa y continúa progresando para lograr metas fundamentales para el éxito de Renown”. En su nueva función como directora de operaciones del Renown South Meadows Medical Center, la Dra. Lee trabajará con Jennifer Allen, máster en enfermería, directora de enfermería, y el equipo y el personal médico de liderazgo del South Meadows para conducir al South Meadows hacia el logro de sus objetivos estratégicos y operativos. La Dra. Lee es una médica ejecutiva experimentada y dinámica y una líder operativa con trayectoria en crecimiento de servicios, calidad clínica, comunicación con los pacientes y ejecución. Tiene experiencia en colaboración interfuncional y es reconocida a nivel nacional por la administración de cambios organizacionales. La Dra. Lee, certificada por el consejo en medicina interna y psiquiatría, ha basado su práctica clínica como médica hospitalaria en la conexión entre la mente y el cuerpo y en un modelo de colaboración con pacientes y familias. La Dra. Lee se unió a Renown Health como presidenta de Especialidades Médicas en el verano de 2020 para administrar las prácticas médicas hospitalarias. Fue ascendida a directora médica del Renown Regional Medical Center en febrero de 2021 para supervisar las operaciones clínicas de pacientes hospitalizados, incluyendo duración de la hospitalización, capacidad hospitalaria, funcionalidad de administración de la atención, rondas interdisciplinarias y servicios para el personal médico. Desde septiembre de 2021, como directora médica de Cuidados Intensivos de Renown, ha sido responsable de las operaciones clínicas, de la dirección estratégica, de la gestión de médicos por hospital, de la Oficina del Personal Médico, de los estándares regulatorios y de los resultados financieros y de calidad para el Renown Regional Medical Center, el Renown South Meadows Medical Center y el Renown Rehabilitation Hospital. Antes de trabajar en Renown, la Dra. Lee se desempeñó como jefa de Medicina Hospitalaria en Carilion Clinic, un sistema de salud integrado sin fines de lucro con siete centros y sede central en Roanoke, Virginia. La Dra. Lee es egresada de la University of Massachusetts Amherst (MBA), la Facultad de Medicina Osteopática (DO) de la Nova Southeastern University y de la Duke University (BA). Es miembro activo del American College of Healthcare Executives y de la American Association for Physician Leadership. El Renown South Meadows Medical Center, ubicado en el sur de Reno, es un hospital comunitario de cuidados intensivos con 76 camas que ofrece servicios médicos y quirúrgicos excepcionales en un ambiente propicio. El Renown South Meadows Medical Center alberga al único Departamento de Emergencias 24/7 del sur de Reno y cuenta con médicos de emergencia certificados por el consejo. El Renown South Meadows Medical Center ofrece atención avanzada a los pacientes, lo cual incluye atención primaria integral; servicios de radiografías e imágenes; servicios de laboratorio; atención cardíaca; obstetricia/ginecología; servicios de rehabilitación física y de rehabilitación pulmonar; medicina nuclear y servicios quirúrgicos, que incluyen ortopedia. Como organización sin fines de lucro, el equipo del Renown South Meadows Medical Center acepta su papel en mejorar la salud y el bienestar de las personas y las comunidades a las que sirven y presta los servicios de atención médica necesarios, independientemente de la raza, el credo, el sexo, la nacionalidad, la discapacidad, la edad o la capacidad de pago. Además, el Renown South Meadows Medical Center ha sido reconocido a nivel nacional por brindar atención y servicios de la más alta calidad. Entre las menciones se incluyen: En los rankings de mejores hospitales de U.S. News and World Report, el Renown South Meadows ocupa el primer puesto en el estado de Nevada (junto con el Carson Tahoe Medical Center) para 2020. El Renown South Meadows obtuvo la calificación de sobresaliente para reemplazo de cadera, reemplazo de rodilla y enfermedad pulmonar obstructiva crónica (EPOC). La calificación de un hospital se basa en múltiples categorías de datos, que incluyen resultados de los pacientes, seguridad y volúmenes. Los hospitales calificados como sobresalientes eran significativamente mejores que el promedio nacional. El Renown South Meadows Medical Center recibió la acreditación The Joint Commission’s Gold Seal of Approval® para reemplazo total de rodilla, reemplazo total de cadera y reemplazo total de hombro y fue reconocido en el programa Top Performer on Key Quality Measures®. La Dra. Lee dice que “entiende que la atención médica actual se trata tanto de las habilidades sociales y de navegar diferentes relaciones como del conocimiento clínico”. A lo largo de su carrera profesional, la Dra. Lee ha hecho mucho para contribuir a una cultura de innovación y transformación. La Dra. Lee cree que “los proveedores necesitan médicos, enfermeros y equipos de atención que tengan una alta adaptabilidad, flexibilidad y, sobre todo, la capacidad de cuidar de otros y ser amables”. La Dra. Lee brinda asesoramiento a los equipos para que sean receptivos, empáticos, conscientes de la situación y empleen sus habilidades clínicas en el nivel más alto. A menudo formulará preguntas a su equipo para comprender cómo están “programados”, a fin de impulsar la innovación y la transformación, y fomentar la cultura y el trabajo en equipo. Ha contratado y capacitado a más de 100 médicos hospitalarios, muchas de ellas mujeres, y ha ascendido y servido como referencia para cientos de enfermeros, líderes de personal y proveedores de atención avanzada. La Dra. Lee se desempeña como mentora para otras mujeres y hombres que aspiran al liderazgo médico y de la atención médica. El equipo del Renown South Meadows Medical Center está en la búsqueda de excelentes empleados para ocupar puestos de servicio; postule en línea en https://careers.renown.org/.

Leer más About La Dra. Susan Lee dirigirá el Renown South Meadows Medical Center

Experienced leader to support physicians at Renown Regional and Renown South Meadows Medical Centers Renown Health is pleased to announce that Adnan “Eddy” Akbar, MD, will serve as Chief Medical Officer for Renown Acute Care, overseeing physicians at Renown Regional Medical Center and Renown South Meadows Medical Center. Renown Health is the region's only Level II Trauma Center, serving more than 1 million people and a 100,000 square mile reach – across Nevada, Lake Tahoe and eastern California. Dr. Akbar begins his new role on July 25, succeeding former Chief Medical Officer for Acute Care, Dr. Susan Lee, who was promoted to Chief Operating Officer at Renown South Meadows Medical Center on 7 de marzo de 2022. Thomas Graf, MD, CEO for Renown Health, announced Dr. Akbar’s internal promotion today by writing, “Embracing our vision to improve the health of our community, we are empowering leaders to play a greater role in improving physician, employee and patient experiences; growing services to our community; providing Reliable and Exact Care® and meeting rigorous standards for operational excellence and efficiency.” Dr. Graf noted that he was excited as, “Dr. Akbar expands his role, promotes a spirit of unity across the enterprise, and continues to make progress on achieving goals central to Renown’s success.” In his new role as Chief Medical Officer for Acute Care, Dr. Akbar will join Dr. Rahul Mediwala, Chief Medical Officer for Health Services, to lead physicians and clinicians across the Renown enterprise. Dr. Akbar will report directly to Chris Nicholas, Chief Executive Officer for Renown Regional Medical Center. Dr. Akbar is an experienced, dynamic physician executive and operational leader with a record of hospital operations, medical staff leadership and engagement, quality improvement, patient safety, patient experience, risk management, utilization management and clinical documentation improvement. Chris Nicholas, Chief Executive Officer of Renown Regional Medical Center wrote, “Over the last seven years and through all the physician leadership positions he has held, Dr. Akbar has had an intense focus on improving patient care, driving hospital and operational improvements, and demonstrating the best of Renown’s mission, vision and values. Renown has a national reputation for delivering health care that is affordable, accessible and of the highest quality and I look forward to working with Dr. Akbar to engage physicians and administrators in an agenda that supports this vision.” Dr. Susan Lee, Chief Operations Officer of Renown South Meadows Medical Center added, “As we considered the needs of the organization and our future, we determined that Dr. Akbar was the right person to lead physicians across Acute Services. In addition, Dr. Akbar has demonstrated strong and engaging leadership with physicians, nurses, the senior management team and across our hospitals and we are confident in Eddy’s ability to contribute to the great progress that Renown Health is making in becoming the best place to practice medicine and to receive care.” Dr. Akbar has been with Renown Health for seven years, previously serving as Secretary of Medical Staff, an Internal Medicine physician, Chair of the Department of Medicine, Division Chief for Hospital Medicine and most recently as a hospitalist physician of Renown Medical Group and Associate Chief Medical Officer of Renown Regional Medical Center. Dr. Akbar is an Assistant Professor of Medicine at University of Nevada-Reno, School of Medicine and a member of the Clinical Faculty at St. Georges University School of Medicine, Grenada. Dr. Akbar is fluent in four languages including Urdu, Pushto and Hindi. Dr. Akbar completed his residency in internal medicine at Cleveland Clinic. He is a Diplomat of the American Board of Internal Medicine, and earned his medical degree from Aga Khan Medical College in Karachi, Pakistan. Dr. Akbar is completing his master’s in healthcare administration from Cornell University. Dr. Akbar’s research interests include observation criteria and appropriate utilization management of hospitalized patients, development and usage of dedicated Epic order sets to improve patient care and outcomes, advancement and development of Milestone appropriate care during acute hospitalization and transitional care policies to reduce hospital readmissions and improve patient care. In U.S. News and World Report Best Hospitals rankings, Renown Regional is #1 in the State of Nevada for 2021. Ningún otro hospital en Nevada obtuvo el reconocimiento de U.S. News. Renown South Meadows was listed #1 in the State of Nevada (tied with Carson Tahoe Medical Center) for 2021. Renown Regional Medical Center is High Performing, its highest rating possible, for Heart Failure, Colon Cancer Surgery and Chronic Obstructive Pulmonary Disease. El Renown South Meadows obtuvo la calificación de sobresaliente para reemplazo de cadera, reemplazo de rodilla y enfermedad pulmonar obstructiva crónica (EPOC). La calificación de un hospital se basa en múltiples categorías de datos, que incluyen resultados de los pacientes, seguridad y volúmenes. Los hospitales calificados como sobresalientes eran significativamente mejores que el promedio nacional. The team at Renown Health is seeking great employees for careers in service; apply online at https://careers.renown.org/. Acerca de Renown Health Renown Health es la red de atención médica integrada de administración local y sin fines de lucro más grande de la región, que presta servicios a Nevada, Lake Tahoe y el noreste de California. Con una fuerza laboral diversa de más de 7,000 empleados, Renown ha fomentado una cultura de excelencia, determinación e innovación de larga data. La organización se compone de un centro de urgencias, dos hospitales de cuidados agudos, un hospital infantil, un hospital de rehabilitación, un grupo médico y una red de atención de urgencias y Hometown Health, la compañía de seguros sin fines de lucro más grande de la región y de propiedad local, Hometown Health. Actualmente, Renown está inscribiendo participantes en el estudio genético de salud poblacional basado en la comunidad más grande del mundo, el Healthy Nevada Project®.

Leer más About Adnan Akbar, MD, Appointed Chief Medical Officer for Renown Acute Care

Renown Health is pleased to announce that Samuel K. Weller, MHPA, will serve as Chief Executive Officer for Renown South Meadows Medical Center, a 118-bed acute care community hospital and Renown Rehabilitation Hospital, a 62-bed physical rehabilitation hospital in Reno, Nev. The position was formerly held by Chris Nicholas, FACHE, who was promoted in March 2022 to serve as CEO of 808-bed Renown Regional Medical Center in Reno. Renown Health is the largest and only locally owned not-for-profit, charitable healthcare network in Reno, serving over 1 million people and 100,000 square miles between Salt Lake City and Sacramento. As CEO, Mr. Weller will work with the South Meadows and Rehabilitation leadership, medical staff, and team to achieve patient care, efficiency, and operational goals.  “We are excited to have Sam join the Renown Health senior leadership team at this pivotal moment in our history,” said Dr. Brian Erling, Renown’s president and CEO. “Sam is a dyamic health care executive with a solid record of advancing acute and ambulatory operations while collaborating with physicians and clinicians to expand services, enhance clinical quality, and exceed customer service expectations. Sam leads with integrity and a people-first approach which are essential to deliver on our mission to improve the health and well-being of the people and communities we serve.” Mr. Weller comes to Renown from Centura Health where he served as Group Vice President of Physician Enterprise for Greater Colorado and Kansas, overseeing physician services across a Level 1 Trauma hospital, eight Level III Trauma hospitals, two Critical Access/Trauma IV hospitals and numerous primary care and specialty practices. He previously served as Director of Strategy and Ambulatory Practices for St. Anthony Summit Medical Center in Summit County, CO overseeing hospital and ambulatory operations for the Rocky Mountain region; and Group Manager Business Development in Denver. Mr. Weller is a graduate of Washington State University with a master’s degree in health policy and administration (MHPA) and a Bachelor of Science degree in Business Finance from Brigham Young University-Idaho. “I love health care because it is about people helping people,” says Sam Weller. “Renown is the most valued and trusted system of health for northern Nevadans, and working together, I am excited to help transform care for our community and improve the quality of life for generations to come.”  South Reno continues to grow, and consumer demand continues to increase for Renown medical providers and facilities. The South Meadows campus, which opened more than 15 years ago in February 2004, is currently improving existing facilities, and expanding service offerings to meet expressed needs of the community. Renown South Meadows Medical Center features private patient rooms for hospital stays, and will add additional private rooms, bringing the total to 73 private rooms when work is done this September.  Weller will assume his new duties on June 26.  Renown South Meadows Medical Center has been nationally recognized for providing the highest quality care and service.  In U.S. News and World Report Best Hospital rankings, Renown South Meadows was listed #1 in the State of Nevada (tied with Carson Tahoe Medical Center) for 2020. El Renown South Meadows obtuvo la calificación de sobresaliente para reemplazo de cadera, reemplazo de rodilla y enfermedad pulmonar obstructiva crónica (EPOC). A hospital's score is based on multiple data categories, including patient outcomes, safety, and volumes. Los hospitales calificados como sobresalientes eran significativamente mejores que el promedio nacional. Renown Regional Medical Center was listed #1 for the State of Nevada in U.S. News and World Report Best Hospital listing for 2021 and 2022.  Sam and the team at Renown South Meadows Medical Center and Renown Rehabilitation Hospital are hiring great physicians, nurses and associates for careers in service; apply online at renown.org/careers, and volunteers to assist patients and their families at renown.org/About/Volunteers. Acerca de Renown Health Renown Health es la red de atención médica integrada de administración local y sin fines de lucro más grande de la región, que presta servicios a Nevada, Lake Tahoe y el noreste de California. With a diverse workforce of more than 7,000 associates, Renown has fostered a longstanding culture of excellence, determination, and innovation. La organización se compone de un centro de urgencias, dos hospitales de cuidados agudos, un hospital infantil, un hospital de rehabilitación, un grupo médico y una red de atención de urgencias y Hometown Health, la compañía de seguros sin fines de lucro más grande de la región y de propiedad local, Hometown Health. Renown is currently hiring great physicians, nurses and associates for careers in service; apply online at renown.org/careers and volunteers to assist patients and their families at renown.org/About/Volunteers.

Leer más About Samuel K. Weller Appointed CEO for Renown South Meadows Medical Center and Renown Rehabilitation Hospital

Renown Health is pleased to announce that Kate A. Ward, Pharm.D., BCPS, has been promoted to serve as Vice President, Oncology for Renown Regional Medical Center.    Dr. Ward has over fourteen years of service to the organization, most recently as Director of Clinical Pharmacy responsible for the oversight of all clinical pharmacy activities at Renown Regional Medical Center, Renown South Meadows Medical Center, and Renown Rehabilitation Hospital. Additionally, Dr. Ward is the Residency Director of the Post-Graduate Year 1 (PGY1) Pharmacy Practice Residency at Renown. Over the last decade at Renown, Dr. Ward has served as Pharmacy Clinical Manager, Pharmacy Clinical Coordinator and Clinical Pharmacist.   Dr. Ward will bring her pharmacy clinical service experience (including ICU, Outpatient Infusion, Pediatrics, Oncology and Emergency Services), Inpatient Care, Clinical Research, and Hospital Formulary Management, Electronic Medical Record Integration and Optimization to this important new role.   As a dyad partner with Max J. Coppes, MD, PhD, MBA, Director of the William N. Pennington Cancer Institute at Renown, she will bring her clinical, operational, regulatory, and administrative experience to lead the oncology division. Dr. Ward, Dr. Coppes and the dedicated team will advance Renown’s mission to expand care, prevention, screening, research, and education with the goal of establishing the first National Institutes of Health, NCI designated Cancer Center for our State.   “We are thrilled to welcome Dr. Ward as our new Vice President of Oncology. She brings a wealth of experience and a passion for advancing patient care. Dr. Ward will play a pivotal role in sharing the future our oncology division and furthering our commitment to providing exceptional care,” said Chris Nicholas, CEO of Renown Regional Medical Center.    As a licensed pharmacist, Dr. Ward holds a Doctor of Pharmacy degree from the University of Colorado, Health Sciences Center. The Pharm.D. is a professional degree like a Doctor of Medicine (MD) or Doctor of Dental Surgery (DDS). As a doctorate, it represents the increasing responsibility pharmacists have in healthcare systems and the high trust Americans have in pharmacists.    Dr. Ward completed her residency at Stanford Hospital and Clinics. She graduated from the University of Nevada, Reno with her bachelor’s degree in Nutritional Sciences. Dr. Ward is active in several professional associations and currently serves as a Pharmacy Board member for HealthTrust; Vice Chair of the American Society of Health System Pharmacists® Council on Therapeutics; and Vice Chair for the Silver State Scripts Board for the State of Nevada. Dr. Ward was the 2022 recipient of the Nevada Society of Health System Pharmacists (NVSHP) President’s Award. Acerca de Renown Health Renown Health es la red de atención médica integrada de administración local y sin fines de lucro más grande de la región, que presta servicios a Nevada, Lake Tahoe y el noreste de California. Con una fuerza laboral diversa de más de 7,000 empleados, Renown ha fomentado una cultura de excelencia, determinación e innovación de larga data. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the locally owned not-for-profit insurance company, Hometown Health. To join the Renown Health team, visit renown.org/careers.

Leer más About Exceptional Talent Joins William N. Pennington Cancer Institute at Renown; Dr. Kate Ward Brings Expertise and Vision as Vice President of Oncology Division

Chuck Podesta, national IT leader to use technology to improve the health and well-being of Nevadans. Renown Health is pleased to announce Charles (Chuck) Podesta has been named Chief Information Officer. Podesta es un ejecutivo experimentado con más de 30 años de experiencia al frente de algunos de los mejores equipos de TI de la industria de atención médica del país. He has literally worked from coast to coast and is excited to bring his talents to Nevada. “We are pleased to bring an experienced and talented leader like Chuck Podesta to lead our information and technology areas at Renown,” said Tony Slonim, MD, DrPH, President & CEO of Renown. “As Chief Information Officer, he will have the opportunity to foster a culture of innovation and excellence in information technology which serves hundreds of thousands of people across the state and the nation. Chuck will use the power of technology to bring a new level of convenience to patients and providers and will use his talents and team to improve the health and well-being of Nevadans.” Chuck most recently served as Interim Chief Information Officer for UCONN Health’s John Dempsey Medical Center, School of Medicine and Clinical Research IT. Prior to that, Chuck served as CIO for UCI Health/UC Irvine School of Medicine and the University of California Health System. He also served as CIO for University of Vermont Health Network/Fletcher Allen Health; Steward Health/Caritas Christi Healthcare; Berkshire Health; Baystate Health and UMASS Medical Center, all in the New England area. Podesta está especializado en crear planes tecnológicos estratégicos, los dota de recursos y los implementa; maximizar el poder del registro médico electrónico EPIC; racionalizar la gobernanza y las prioridades; alinear las necesidades informáticas médicas y de TI en todas las entidades afiliadas, lo que incluye el entorno de las facultades de medicina, las organizaciones de atención responsable (Accountable Care Organization, ACO), las redes clínicas integradas (Clinically Integrated Networks, CIN) y los consultorios médicos; establecer asociaciones para implementar las mejores herramientas digitales impulsadas por el cliente; liderar la participación en intercambios de información de salud (health information exchange, HIE) en todo el estado, y entrenar y asesora a los equipos de TI.   “Chuck’s experience and strengths in a variety of diverse and complex environments make him the perfect leader for us at this important time in our history,” explains Josiah (Sy) Johnson, Chief of Staff for Renown. Chuck will assure we are leading with innovative and contemporary approaches and integrating technology and expertise in our ongoing pursuit of excellence in improving health and healthcare in Nevada. “I am honored and excited to join the Renown Health family and the northern Nevada community,” says Chuck Podesta, Chief Information Officer. “I am impressed with the innovation and transformation at Renown; which has earned it a reputation as one of the nation’s leading health systems. I look forward to joining Renown Health at this exciting time in its history. I am excited to bring my skills and experience to create a positive experience when people use our technology. I am looking forward to leading the organization on this important journey.” Podesta is a graduate of the Massachusetts College of Liberal Arts and an active member of CHIME, HIMSS and the Society for Information Management (SIM). Podesta comenzará en Renown el 12 de julio.   About Renown Health Renown Health is the region’s largest, local not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Con una fuerza laboral diversa de más de 7,200 empleados, Renown ha fomentado una cultura de excelencia, determinación e innovación de larga data. La organización se compone de un centro de urgencias, dos hospitales de cuidados agudos, un hospital infantil, un hospital de rehabilitación, un grupo médico y una red de atención de urgencias y Hometown Health, la compañía de seguros sin fines de lucro más grande de la región y de propiedad local, Hometown Health. Clinical institutes include: Cancer, Heart and Vascular Heath and Neurosciences. Actualmente, Renown está inscribiendo participantes en el estudio genético de salud poblacional basado en la comunidad más grande del mundo, el Healthy Nevada Project®. For more information, visit renown.org.

Leer más About Renown Health le da la bienvenida al nuevo director de Tecnología de la Información

Lanzada en asociación con el Desert Research Institute, una nueva investigación del proyecto Healthy Nevada Project® determina que un diagnóstico confirmado no siempre produce cambios en el cuidado del paciente. El hecho de entregar a las personas información de salud que pueda cambiar sus vidas no garantiza que las personas, o sus proveedores de atención médica, actuarán en consecuencia. La educación de seguimiento y las conversaciones sobre los planes de cuidado ejecutables con los pacientes y sus médicos son los próximos pasos clave, de acuerdo con la nueva investigación del Healthy Nevada Project. El Healthy Nevada Project es un proyecto de investigación y detección genética que se lanzó en 2016 como una asociación entre DRI y Renown Health. El proyecto ahora tiene más de 50,000 participantes y cuenta con secuenciación genética proporcionada por Helix. Entre septiembre de 2018 y septiembre de 2020, el Healthy Nevada Project notificó exitosamente a 293 participantes que estaban genéticamente en riesgo de desarrollar cáncer de pecho y ovario, síndrome de Lynch o hipercolesterolemia familiar hereditarios, tres afecciones genéticas comunes conocidas colectivamente como afecciones de Nivel 1 de los Centros para el Control y la Prevención de Enfermedades (Centers for Disease Control and Prevention, CDC). En un estudio publicado hoy en Frontiers in Genetics, los científicos del Healthy Nevada Project analizaron qué impacto tuvo el hecho de notificar a un paciente sobre un resultado positivo para una condición de Nivel 1 de los CDC en el cuidado que recibió el paciente en los meses y años posteriores. Según sus resultados, entre los 293 participantes del Healthy Nevada Project que fueron notificados del riesgo genético de desarrollar una afección del Nivel 1 de los CDC, el 71 % de participantes con registros médicos electrónicos compartieron sus hallazgos con los proveedores de atención médica. Sin embargo, solo el 30 % de los registros médicos electrónicos de estos pacientes contenía documentación del diagnóstico genético, y solo el 10 % de los pacientes examinados experimentó un posible cambio en el cuidado después de recibir los resultados de su examen de detección genético. “El Healthy Nevada Project se implementó con un enfoque ‘sin intervención’ en el que los participantes reciben sus hallazgos y deciden con quiénes y cuándo desean compartirlos. Los hallazgos no se agregaron automáticamente a sus registros médicos electrónicos”, explicó el Dr. Gai Elhanan, científico de datos médicos en DRI y coautor del estudio. “Lo que estamos aprendiendo ahora es que para garantizar que los hallazgos genéticos importantes se integren en el régimen de cuidado, es importante que su incorporación en los registros médicos electrónicos forme parte del estudio”. Este estudio se basa en investigaciones anteriores del Healthy Nevada Project publicadas en Nature Medicine. En ellas se demuestra la importancia de realizar exámenes de detección para las afecciones del Nivel 1 de los CDC, las cuales afectan a aproximadamente a 1 de cada 75 personas y se pueden mitigar e incluso se puede evitar que se conviertan en enfermedades cuando se detectan en forma temprana. Este estudio determinó que hasta el 90 % de los casos con afecciones del Nivel 1 de los CDC no son detectados por los proveedores clínicos en las evaluaciones y los exámenes de detección que se realizan durante las visitas de cuidado clínico habitual. Durante el estudio actual, los científicos del Healthy Nevada Project descubrieron que el 19 % de participantes estudiados ya había desarrollado una de las afecciones del Nivel 1 de los CDC y, por lo tanto, podrían haberse beneficiado de una notificación más temprana sobre su afección. El equipo del estudio espera que sus hallazgos estimulen a los residentes de Nevada a obtener pruebas genéticas para estas afecciones relativamente comunes. Incluso si las personas son mayores o ya han sufrido enfermedades relacionadas con estas afecciones, las pruebas también podrían ser beneficiosas para los hermanos, los niños y los nietos que también pueden estar en riesgo y que posteriormente podrían someterse a exámenes de detección en caso de un hallazgo positivo. El equipo del estudio también incita a informar a los proveedores de atención médica sobre la importancia de incorporar diagnósticos genéticos en las recomendaciones farmacéuticas (por ejemplo, para la hipercolesterolemia familiar) y de tratamiento a los pacientes. “Como resultado de este análisis, los médicos de Renown Health y los investigadores del Healthy Nevada Project han logrado cambios significativos, lo que incluye la obtención del consentimiento informado de los participantes para incorporar hallazgos positivos de sus informes genéticos directamente en su registro médico electrónico”, explicó Daniel Kiser, M.S., científico auxiliar de investigación de ciencia de datos en DRI y coautor del estudio. “Esto ayudará tanto a los participantes como a sus proveedores de cuidado clínico, y a todo el estado a maximizar los beneficios a largo plazo de los exámenes de detección genéticos voluntarios basados en la población del Healthy Nevada Project”. Información adicional: El texto completo del estudio, Incomplete Penetrance of Population-Based Genetic Screening Results in Electronic Health Record, está disponible en Frontiers in Genetics: https://www.frontiersin.org/articles/10.3389/fgene.2022.866169/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Genetics&id=866169. Este proyecto fue financiado por Renown Health, fundación de Renown Health y la Oficina de Desarrollo Económico del Gobernador de Nevada. Entre los autores del estudio se incluyen Gai Elhanan (DRI), Daniel Kiser (DRI), Iva Neveux (DRI), Shaun Dabe (Renown Health), Alexander Bolze (Helix), William Metcalf (DRI), James Lu (Helix) y Joseph Grzymski (DRI/Renown Health). Para obtener más información sobre el Healthy Nevada Project® o para solicitar un examen de detección genético, visite: https://healthynv.org/ Acerca del DRI El Desert Research Institute (DRI) es un reconocido líder mundial en investigación ambiental básica y aplicada. Comprometidos con la excelencia e integridad científicas, el cuerpo docente del DRI, los estudiantes que trabajan juntos y el personal han desarrollado conocimientos científicos y tecnologías innovadoras en proyectos de investigación en todo el mundo. Desde 1959, la investigación de DRI ha profundizado el conocimiento científico sobre temas que van desde el impacto de los seres humanos en el medioambiente hasta el impacto del medioambiente en los seres humanos. Los hallazgos científicos impactantes y las soluciones inspiradoras del DRI apoyan la economía diversa de Nevada, proporcionan oportunidades educativas basadas en la ciencia e informan a legisladores, líderes empresariales y miembros de la comunidad. El DRI tiene campus en Las Vegas y Reno y funciona como el grupo de investigación sin fines de lucro del Sistema de Educación Superior de Nevada. Para obtener más información, visite www.dri.edu. Acerca de Renown Health Renown Health es la red de atención médica integrada de administración local y sin fines de lucro más grande de la región, que presta servicios a Nevada, Lake Tahoe y el noreste de California. Con una fuerza laboral diversa de más de 7,000 empleados, Renown ha fomentado una cultura de excelencia, determinación e innovación de larga data. La organización se compone de un centro de urgencias, dos hospitales de cuidados agudos, un hospital infantil, un hospital de rehabilitación, un grupo médico y una red de atención de urgencias y Hometown Health, la compañía de seguros sin fines de lucro más grande de la región y de propiedad local, Hometown Health. Actualmente, Renown está inscribiendo participantes en el estudio genético de salud poblacional basado en la comunidad más grande del mundo, el Healthy Nevada Project®. Visite renown.org para obtener más información. Acerca de Helix Helix es la compañía líder en genómica y vigilancia viral de la población cuyas operaciones se basan en el cuidado clínico, la investigación y el análisis de datos. Helix permite que los sistemas de salud, las empresas de ciencias biológicas, los pagadores y los socios gubernamentales aceleren la integración de los datos genómicos en el cuidado médico del paciente y en la toma de decisiones de salud pública. Obtenga más información en www.helix.com.

Leer más About Un estudio demuestra la importancia de garantizar el seguimiento del participante y del proveedor después de obtener el resultado de un examen de detección genético

Renown Health is pleased to announce the appointment of Anna Loomis, MBA, as its new Chief Financial Officer (CFO), effective 1ro de julio de 2024. Ms. Loomis will oversee all aspects of financial management for Renown Health including budgeting, financial planning, revenue cycle management, supply chain and strategic investments for Nevada’s #1 ranked health care organization.    Before joining Renown, Ms. Loomis served as Senior Vice President (SVP) and CFO with Portland-based Legacy Health, and prior to that as SVP and Chief Financial Officer for Washington-based MultiCare for more than 15 years.  With over 20 years in finance leadership and strategy, Ms. Loomis has led several transformative efforts to strengthen the organizations and build partnerships.    “We are thrilled to welcome Anna Loomis to our executive team,” said Brian Erling, MD, MBA, President & CEO for Renown Health. “Anna is an approachable, innovative, and resilient leader. Her proven track record of financial stewardship and her deep understanding of the complexities of the healthcare landscape make her an ideal fit for the team. The essential role that Renown Health plays as the only local, not-for-profit, charitable healthcare network in Washoe County will be furthered by her commitment. We are confident that with her guidance and expertise, we will continue to strengthen our financial position while advancing our mission to deliver the highest quality care and service to patients.”    Anna earned her master’s and bachelor’s degree in business administration from Pacific Lutheran University (Tacoma, WA); completed a finance fellowship with The Academy GE Fellows Program and serves on the Board of Directors for PacificSource health plans.   As of Aug. 2023, Fitch Ratings affirmed the 'A+' long-term rating on the series 2020A, 2020B, 2015A and 2016A bonds issued on behalf of Renown Health, NV by Public Finance Authority (Renown Regional Medical Center Project). In addition, Fitch has affirmed Renown's IDR at 'A+'. Renown's 'A+' revenue bond ratings and the Outlook revision to Stable are primarily driven by the system's midrange operating risk profile assessment, which has rebounded significantly over the past 12-months. Both the rating and Stable Outlook incorporate Renown's position as the service area's single largest provider of high-end acute care services and maintenance of the leading market position, with approximately two-thirds of all patients in northern Nevada seeking care at Renown. The rating is further informed by Renown's solid balance sheet metrics, which remain intact at or near historical levels. Given significant consumer demand for Renown providers and services, a master facility planning process and strategic planning process has been undertaken to ensure that Renown has adequate bed and procedure capacity, spaces to accommodate new technology and services to meet the needs of a growing patient base and community. As the region’s only Level 2 Trauma Center for both adults and children, Renown serves over 1 million people and 100,000 square miles across Nevada, Lake Tahoe, and northeast California. In U.S. News and World Report Best Hospital Rankings, Renown Regional Medical Center has been named #1 in the State of Nevada for the last three years.   Renown Health is the region’s largest, locally governed, not-for-profit integrated health care network serving Nevada, Lake Tahoe, and northeast California. With a diverse workforce of more than 7,200 employees, Renown has fostered a longstanding culture of excellence, determination, and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the locally owned not-for-profit insurance company, Hometown Health. Visite renown.org para obtener más información.

Leer más About Renown Health Appoints Anna Loomis MBA As Chief Financial Officer

Juntos, realizarán pruebas a más de 30,000 participantes del estudio elegibles antes de 2023 para determinar el riesgo de cirrosis y enfermedades relacionadas con el hígado. Renown Institute for Health Innovation (IHI) announced today that the organization and Gilead Sciences, Inc. will be joining forces with Siemens Healthineers to offer the Enhanced Liver Fibrosis (ELF™) Test to people with risks for nonalcoholic steatohepatitis (NASH) enrolled in the Healthy Nevada Project (HNP). The ELF Test will help identify people most at risk for progressing to cirrhosis and liver-related outcomes and allow healthcare providers to intervene before irreparable damage occurs. This noninvasive blood test uses three serum biomarkers to create an ELF score from a predefined algorithm, which can be used by doctors to help evaluate if a patient requires increased medical care and monitoring for their condition. La enfermedad de hígado graso no alcohólico (EHGNA), que incluye la EHNA, es frecuente en Nevada y está subdiagnosticada, y probablemente afecte a más de 500,000 adultos en nuestro estado. If undetected and untreated, NASH can result in liver cirrhosis and may require liver transplantation or lead to death. Hay más de 12,000 personas en la lista de espera para trasplante de hígado en los EE. UU. y esta cifra continúa aumentando debido al incremento en la prevalencia de la EHGNA. “Thanks to important data collected through our Nonalcoholic Steatohepatitis Liver Disease Genome Atlas study, we now know that NASH is prevalent in the state of Nevada,” said Tony Slonim, M.D., DrPH, FACHE, president and CEO of Renown Health. “We are proud to expand our partnership with Gilead and begin working with Siemens Healthineers to improve health of those with liver disease and to take early detection one step further by offering Enhanced Liver Fibrosis, ELF testing for patients of Renown Health. This test provides our team of highly-skilled physicians an advanced, noninvasive method to actively assess dynamic liver fibrosis in study participants and intervene whenever necessary, contributing to a healthier Nevada.”  “Gilead believes that noninvasive tests, including the ELF Test, will help improve the experience of people living with NASH. These tests may help to diagnose liver disease, monitor disease progression and evaluate responses to treatment without the requirement for liver biopsy,” said Rob Myers, MD, Vice President, Liver Fibrosis Clinical Research at Gilead Sciences. “The ELF Test has proven itself to be a valuable tool in NASH management and we hope this partnership will further support its use in routine care.”  “We are very pleased that NASH patients in the Healthy Nevada Project now have access to the ELF Test which offers clinically useful prognostic information for their condition with the convenience of a simple blood test. Using our advanced laboratory expertise together with Renown IHI and Gilead, we can work towards better understanding of NASH and liver disease in a representative patient population,” said Sebastian Kronmueller, Head of Molecular Diagnostics at Siemens Healthineers. “We launched the Healthy Nevada Project to help people understand more about their health, to identify serious health risks, and to give people access to innovations like the ELF Test, so they can live their best lives,” said Renown’s chief scientific officer, Dr. Joseph Grzymski, who is also a research professor at the Desert Research Institute and principal investigator of the Healthy Nevada Project. Es increíblemente gratificante poder informar hallazgos clínicos para ayudar a nuestros 50,000 participantes voluntarios del estudio y asistir a los proveedores de atención médica a ayudar a sus pacientes”. La provisión de la prueba de ELF se basa en una colaboración estratégica anunciada previamente entre el Renown IHI y Gilead en julio de 2019. Esta sociedad en curso tiene como objetivo recopilar y analizar datos de salud genéticos y electrónicos anónimos de 60,000 participantes del estudio elegibles con el fin de mejorar la comprensión de la EHGNA y la EHNA y para potencialmente orientar el desarrollo de opciones de tratamiento para estas enfermedades. Acerca de la EHGNA y la EHNA La EHGNA es una acumulación de grasa en el hígado en personas que no tienen antecedentes de abuso de alcohol. Es normal que el hígado contenga algo de grasa, pero si más del 5 por ciento del contenido hepático es grasa, se considera hígado graso (esteatosis). NASH is the most severe form of NAFLD in which a person has liver cell damage and inflammation of the liver. Inflammation and liver cell damage can cause fibrosis, or scarring of the liver, and can cause decreased liver function (1). The symptoms of NASH are often silent or non-specific, making it difficult to diagnose. Aproximadamente, un tercio de las personas con EHNA desarrollan cirrosis o daño hepático irreversible (2). About the ELF™ Test The ELF Test is a noninvasive blood test that can quickly identify which patients are at an elevated risk for developing cirrhosis and other liver-related clinical events (LREs). In contrast to standard liver enzyme tests that reflect liver damage that has already occurred, the ELF Test combines three serum direct biomarkers of active fibrosis. The ELF Test algorithm measures each of these biomarkers to create an ELF score, which can be used as an aid to assess the risk for future disease progression. Doctors may use this ELF score to help evaluate if a patient requires increased medical care and monitoring for their condition. Individuals interested in determining their risk for NASH and its progression are encouraged to enroll in the Nonalcoholic Steatohepatitis Liver Disease Genome Atlas study. Those who have already consented and participated in the study will be contacted with more information on how to receive an ELF blood test. Para obtener más información o para inscribirse, comuníquese a la casilla de correo RenownIHI@renown.org o al teléfono (775) 982-6914. The Enhanced Liver Fibrosis (ELF™) Test kit is not available for sale in the U.S. Product availability may vary from country to country and is subject to varying regulatory requirements.  In the U.S., the ELF Testing Service is available from Siemens Healthcare Laboratory, LLC (SHL), a CLIA-certified laboratory located in Berkeley, Calif. The ELF Testing Service, including the establishment of performance characteristics, was developed by SHL. The ELF Test has not been cleared or approved by the U.S. Food and Drug Administration. SHL is regulated under CLIA as qualified to perform high complexity testing. The ELF Test is used for clinical purposes and should not be regarded as investigational use only or research use only. About Renown Health Renown Health is the region’s largest, locally owned and governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Con una fuerza laboral diversa de más de 7,000 empleados, Renown ha fomentado una cultura de excelencia, determinación e innovación de larga data. La organización se compone de un centro de urgencias, dos hospitales de cuidados agudos, un hospital infantil, un hospital de rehabilitación, un grupo médico y una red de atención de urgencias y Hometown Health, la compañía de seguros sin fines de lucro más grande de la región y de propiedad local, Hometown Health. Renown’s institute model addresses social determinants of health and includes: Child Health, Behavioral Health & Addiction, Healthy Aging and Health Innovation. Clinical institutes include: Cancer, Heart and Vascular Health, Neurosciences and Robotic Surgery. Actualmente, Renown está inscribiendo participantes en el estudio genético de salud poblacional basado en la comunidad más grande del mundo, el Healthy Nevada Project®. For more information visit, renown.org. About the Renown Institute for Health Innovation Renown Institute for Health Innovation is a collaboration between Renown Health - a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California; and the Desert Research Institute - a recognized world leader in investigating the effects of natural and human-induced environmental change and advancing technologies aimed at assessing a changing planet. Renown IHI research teams are focused on integrating personal healthcare and environmental data with socioeconomic determinants to help Nevada address some of its most complex environmental health problems; while simultaneously expanding the state’s access to leading-edge clinical trials and fostering new connections with biotechnology and pharmaceutical companies. Learn more at healthynv.org. Renown Health es la red de atención médica más completa e integrada de Nevada y mantiene registros médicos electrónicos para 1.02 millones de pacientes registrados. En 2016, Renown Health y el Desert Research Institute crearon el Healthy Nevada Project (HNP), el primer estudio de salud poblacional basado en la comunidad del país. En 2017, el HNP comenzó una sociedad con Helix para aprovechar sus servicios de salud poblacional, la secuenciación Exome+™ y las herramientas de participación del consumidor. The HNP is now an ongoing collaboration between Renown IHI, the Desert Research Institute, a global leader in environmental data and applied research, and Helix, a personal genomics company. HNP combines genetic, environmental, social and clinical data to address individual and community health needs with the goal of improving health across the state and the nation. El HNP actualmente tiene más de 60,000 participantes. For more information, visit healthynv.org.  About Siemens Healthineers Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers ability to provide high-quality, efficient care to patients. En el año fiscal 2020, que finalizó el 30 de septiembre de 2020, Siemens Healthineers, que tiene aproximadamente 54,000 empleados en todo el mundo, generó ingresos por €14.5 mil millones y un EBIT ajustado de €2.2 mil millones. Encontrará más información disponible en www.siemens-healthineers.com.Media Contacto de Siemens Healthineers: Lance LongwellM: 610-448-6341E: lance.longwell@siemens-healthineers.com

Leer más About Renown Institute Expands Partnership to Offer ELF Testing

Clinical researchers with the Healthy Nevada Project co-author research paper with findings that emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively.  Breast cancer is a leading cause of cancer death among women in the United States. According to the American Cancer Society, about 1 in 8 women will develop breast cancer and about 1 in 39 women will die from breast cancer. Breast cancer is associated with increased age, hereditary factors, obesity, and alcohol use. Since 1990, breast cancer death rates have declined progressively due to advancements in treatment and detection. In Nevada there are an estimated 2,310 new breast cancer cases a year, and genetic mutations such as in the genes BRCA1 or BRCA2 remain a top risk factor for this prevalent disease. Recognizing the urgency for progress in breast cancer research, a collaborative effort between physicians, advanced practice providers and scientists from the Healthy Nevada Project® (HNP) and Helix have unveiled groundbreaking research. This study explores how genetic screenings are a necessary supplement to traditional testing methods, together offering more accurate insights into a patient's likelihood of developing breast cancer in the future. HNP is operated by Renown Genomic Medicine and the Institute for Health Innovation and is one of the largest community-based population health studies in the country. Their team works in collaboration with Helix, a leader in precision health that delivers comprehensive genomic solutions. Together, this dynamic partnership aims to understand breast cancer risk factors and pave the way for more effective preventative measures. The combined research team studied 25,591 female HNP participants to evaluate the performance of different genetic screening approaches to identify women at high risk of breast cancer. The results of this research suggest that a combined monogenic, or single-gene, and polygenic, or multi-gene, approach to breast cancer screenings helped produce more accurate results and more closely identify study participants who have a high genetic risk of developing the disease. "Based on this research, we are advocating a shift in approach which would improve breast cancer risk assessment through a combination of effective family history ascertainment and genetic screening,” said Joseph Grzymski, PhD, principal investigator of the Healthy Nevada Project, research professor at the University of Nevada, Reno School of Medicine and co-author of the breast cancer research paper. “This tailored approach, founded on the assessment of individual genetic risk, not only intends to elevate patient well-being but also will improve efficiency and equity in healthcare." Complementing the team’s research on leveraging genetics to identify women at low genetic risk of breast cancer that could safely defer mammogram screenings by five to 10 years that was released in late 2023 in JAMA Oncology, the study suggests that incorporating genetic information can assist in personalizing breast cancer screenings and optimizing the use of screening resources. "Existing disparities persist across various facets of breast cancer screening and treatment; however, genetic screening is clearly a powerful tool to help facilitate early intervention for those at higher risk,” said Jamie Schnell Blitstein, APRN, a primary care nurse practitioner at Renown Health and co-author of the breast cancer research paper. “By placing a heightened focus on risk, we underscore the pivotal role of preventative breast cancer screening.” Despite the availability of effective methods for early screening, co-authors of this research found that 78 percent of women with a family history of breast cancer had their risk ascertained only after a breast cancer diagnosis. The findings emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively.  “These findings that can profoundly impact how healthcare is delivered were only made possible by all the participants who were willing to consent to research,” said Alex Bolze, PhD from Helix and co-author of the publication. “Broad-scale collaboration projects like these between Renown Health and UNR that engage large populations where participants share both their genetic information as well as electronic health records drive advancements in preventative medicine, as well as fundamental biological research.”   The research paper was officially accepted on Jan. 29, 2024, and will be published by Elsevier, Inc. on behalf of the American College of Medical Genetics and Genomics. The contents of the paper will appear in the international journal Genetics in Medicine Open. Read the full article by visiting sciencedirect.com. The Healthy Nevada Project is currently recruiting new study participants. Free to all Nevadans with a saliva sample or blood draw, participants and their referring providers receive access to whole-exome sequencing and clinical grade results that help provide insight into their unique genetic risks tied to heart disease and certain cancers. If you are interested in enrolling in the study, schedule a Virtual Consent Appointment through MyChart or contact the Renown Institute for Health Innovation at RenownIHI@renown.org or (775) 982-6914 to be connected to a Genomic Representative. About Renown Health Renown Health is the region’s largest, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Con una fuerza laboral diversa de más de 7,000 empleados, Renown ha fomentado una cultura de excelencia, determinación e innovación de larga data. La organización se compone de un centro de urgencias, dos hospitales de cuidados agudos, un hospital infantil, un hospital de rehabilitación, un grupo médico y una red de atención de urgencias y Hometown Health, la compañía de seguros sin fines de lucro más grande de la región y de propiedad local, Hometown Health. Renown is currently enrolling participants in the largest community-based genetic population health study, the Healthy Nevada Project®. To join the Renown Health team, visit renown.org/careers. Acerca de Helix Helix es la compañía líder en genómica y vigilancia viral de la población cuyas operaciones se basan en el cuidado clínico, la investigación y el análisis de datos. Helix enables health systems, life sciences companies, payers, and government partners to accelerate the integration of genomic data into patient care and public health decision-making. Learn more at helix.com.

Leer más About Research Shows Genetic Approaches to Breast Cancer Screenings Yield More Accurate Results